Resmed Stock Price, News & Analysis

Resmed (NYSE: RMD) announced that Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at approximately 10:30 a.m. PST in San Francisco.

The company said a live, audio-only webcast will be available via the investor website investor.resmed.com. An audio replay will be posted about 24 hours after the live event and remain accessible for 30 days.

Resmed (NYSE: RMD) received FDA clearance on December 8, 2025 for Personalized Therapy Comfort Settings, marketed as Smart Comfort, an AI-enabled digital medical device that recommends individualized CPAP comfort settings. Smart Comfort uses machine learning trained on more than 100 million nights of de-identified sleep data to adjust pressure ramp, exhale pressure relief and easing-into-therapy settings. A limited U.S. beta for new myAir users paired with AirSense 11 will launch in early 2026, followed by a broader U.S. rollout later in 2026. The feature provides non-prescription comfort recommendations and aims to improve engagement and sustained adherence without changing prescribed therapy settings.

Resmed (NYSE: RMD) reported fiscal Q1 2026 results for the quarter ended September 30, 2025, with revenue $1.336B (up 9% year‑over‑year; +8% constant currency) and gross margin 61.5% (up 290 bps).

Non‑GAAP gross margin rose 280 bps to 62.0%. Income from operations was $446.5M (+15%); non‑GAAP income from operations was $482.1M (+19%). Net income was $348.5M and diluted EPS was $2.37 (non‑GAAP EPS $2.55, +16%). Operating cash flow was $457M. The board declared a quarterly cash dividend of $0.60 per share and repurchased 523,000 shares for $150M.

Resmed (NYSE: RMD) will report first quarter fiscal 2026 results on Thursday, October 30, 2025 after NYSE close. Management will host a live webcast at 1:30 p.m. PDT / 4:30 p.m. EDT (London 8:30 p.m. GMT; Sydney Oct 31 7:30 a.m. AEDT) to discuss financial and operational results and other material information.

Investors can access the webcast at https://investor.resmed.com. A replay will be available on the investor relations site about two hours after the webcast. A phone replay runs from October 30, 2025 through November 13, 2025 with U.S. and international dial-ins and conference ID 13756529.

ResMed (NYSE: RMD) announced its participation in the upcoming Bank of America Global Healthcare Conference 2025 in London. Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer, will present on September 23, 2025 at 1:20 p.m. BST.

The presentation will be available via audio-only webcast on the company's investor relations website, with replay access available for 30 days following the event.

Resmed (NYSE:RMD) has launched the Sleep Institute, a global clinical insights initiative aimed at advancing sleep health science and understanding. The initiative debuts at the World Sleep Congress 2025 in Singapore, focusing on addressing the significant global burden of sleep disorders, including 1 billion people affected by obstructive sleep apnea (OSA) and 852 million adults with clinical insomnia.

The Sleep Institute will publish research, expert perspectives, and real-world data to improve diagnosis and inform clinical strategies. A recent U.S. consumer survey revealed that while over 80% of respondents consider sleep important for health, only one-third reported discussing sleep with healthcare providers in the past six months. The initiative will feature a symposium at the World Sleep Congress addressing OSA underdiagnosis, bringing together experts from Iceland, Singapore, the United States, and Sweden.

ResMed (NYSE:RMD) has published a landmark study in The Lancet Respiratory Medicine projecting that obstructive sleep apnea (OSA) will affect nearly 77 million U.S. adults by 2050, representing a 35% increase from 2020. The research reveals significant demographic shifts, with women experiencing a 65% relative increase to 30.4 million cases, while men will see a 19% increase to 45.9 million cases.

The study, conducted through ResMed's medXcloud academic-industry collaborative, indicates that OSA will impact 46% of adults aged 30-69 by 2050. Notably, the impact of GLP-1 weight loss therapies is expected to be minimal, potentially reducing OSA prevalence by only 4% to 74 million cases. The research emphasizes the urgent need for enhanced screening, earlier diagnosis, and improved healthcare resource allocation to address this growing public health challenge.

Resmed (NYSE:RMD) has achieved significant milestones in innovation with its AirTouch N30i nasal cradle mask winning two Red Dot Awards in Product Design 2025. The mask, launched in October 2024, features the company's first-ever nasal cushion combining fabric with silicone, designed to enhance CPAP therapy comfort and adherence.

The AirTouch N30i received perfect user ratings for comfort features in a multi-center study. This innovation contributes to treating obstructive sleep apnea (OSA), which affects over one billion people globally. Additionally, Resmed announced reaching 10,000 patents and designs in its global portfolio, highlighting its leadership in sleep and respiratory care technology.

ResMed (NYSE: RMD) has announced significant changes to its Board of Directors. Nicole Mowad-Nassar, currently Senior Vice President at AbbVie and President of Specialty and U.S. Therapeutics Operations, has been elected to the board effective August 15, 2025.

Mowad-Nassar brings over 30 years of healthcare industry experience, managing a $6 billion commercial portfolio and overseeing 6,000 employees at AbbVie. She notably led the commercial integration of the $63 billion Allergan acquisition.

Additionally, Rich Sulpizio, who has served on ResMed's board since 2005, will retire following the 2025 Annual Meeting of Stockholders on November 19, 2025. Mowad-Nassar will serve as an independent director on the Compensation and Leadership Development Committee.